STERLING, Va.--(BUSINESS WIRE)--May 3, 2006--WaveLight, Inc. (FSX:WLT) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to treat mixed astigmatism with the wavefront-optimized(TM) ALLEGRETTO WAVE excimer laser system. The indication includes the reduction or elimination of naturally occurring mixed astigmatism of up to 6.00 diopters at the spectacle plane.
